Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00741715 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Efficacy and Safety of AVE5530 Co-administered With Atorvastatin in Primary Hypercholesterolemia
A Phase 3 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,736
- Enrollment target
NCT00741715: Clinical Trial Phase 3 study, sponsored by Sanofi.
NCT00741715 is a Phase 3 study that was terminated before completion, run by Sanofi. The registered enrollment target is 1,736 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (125% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00741715, a Phase 3 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,736 participants
- Enrollment target
Study Summary
The present study is assessing the efficacy and safety of AVE5530 (25mg and 50mg) co-administered with all approved doses of atorvastatin in a double-blind comparison with placebo, AVE5530 alone and atorvastatin alone in the management of patients with primary hypercholesterolemia. The main objective is to evaluate the effects of the association AVE5530+atorvastatin on LDL-C level reduction after 12 weeks of treatment. The effects of AVE5530+atorvastatin on other lipid parameters will be assessed as secondary objectives
Interventions
- DRUG placebo
- DRUG atorvastatin
- DRUG AVE5530
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,736 participants |
| Start Date | 2008-08 |
| Est. Completion | 2009-06 |
| Phase | Phase 3 |
Why NCT00741715 stopped before completion
NCT00741715 is an interventional study that assigns participants to a tested intervention. Its 1,736 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (125% higher).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00741715 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00741715 about?
NCT00741715 is a clinical study titled "Evaluation of Efficacy and Safety of AVE5530 Co-administered With Atorvastatin in Primary Hypercholesterolemia". The present study is assessing the efficacy and safety of AVE5530 (25mg and 50mg) co-administered with all approved doses of atorvastatin in a double-blind comparison with placebo, AVE5530 alone and atorvastatin alone in the management of patients with primary hypercholesterolemia. The main objectiv...
What is the current status of trial NCT00741715?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,736 participants. The study started on 2008-08. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00741715?
The interventions under investigation include: placebo (DRUG), atorvastatin (DRUG), AVE5530 (DRUG).
Who is sponsoring clinical trial NCT00741715?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00741715's enrollment target sits among peer trials
1,736 129th of 2000 higher than 1,871 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04712656 · 1,739 participants
Effects of CPAP Therapy on Blood Pressure and Heart Rate Variability in Obstructive Sleep Apnea
- NCT06413420 · 1,731 participants
SUNOSI® (Solriamfetol) Pregnancy Registry
- NCT06898034 · 1,725 participants
Postpartum Ultrasound Evaluation to Assess Risk of Hemorrhage
- NCT05934487 · 1,750 participants · NA
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia